
In 2005 Lundbeck revamped its global production apparatus in an effort to find out what to keep and which factories to get rid of. Since then, the company has worked with LEAN manufacturing, and the combination of those two factors has ensured that Lundbeck’s production is no longer just working for Lundbeck.
“Having acquired these skills and this capacity, we asked ourselves the question if we shouldn’t start manufacturing for other pharmaceutical companies and cash in on it,” explained Lars Bang, EVP of production in Lundbeck, at last week’s drug manufacturing convention at Christiansborg (Danish parliament building), held by The Danish Association of the Pharmaceutical Industry (LIF).
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer.
Start et gratis virksomhedsprøveabonnementMere fra MedWatch
Evaxion sikrer sig mulighed for at rejse 100 mio dollar
Biotekselskabet Evaxion Biotech, der arbejder med udviklingen af vacciner og immunterapi baseret på kunstig intelligens, har sikret sig muligheden for at rejse 100 mio. dollar til finansieringen af selskabets drift i tider med uro på de finansielle markeder. Rettidig omhu, lyder det fra den adm. direktør.